Responsibility

Progress in 2020

We had nine major approvals for medicines in respiratory, oncology, HIV and immuno-inflammation and nine pivotal trials were started, including for our vaccine candidate for respiratory syncytial virus (RSV). Overall, we now have more than 20 assets in late stage development.

Read more in the Innovation section of our Annual Report.

Progress in 2020

The FDA and EMA approved an age-appropriate formulation of Tivicay, for children living with HIV weighing at least 3kg and from four weeks of age. We announced a product transfer agreement for our RTS,S malaria vaccine with PATH and Bharat Biotech, and we licensed our TB candidate vaccine to the Bill & Melinda Gates Medical Research Institute for further development. In early 2020, we also joined the Partnership to Accelerate New TB Treatments.

Read more here.

Progress in 2020

We became a founding member of the Trinity Challenge collaboration, which aims to use data and analytics to better predict and prevent outbreaks, epidemics and pandemics. We partnered with industry and multilateral organisations to launch the $1 billion AMR Action Fund, aiming to bring two to four novel antibiotics to patients by 2030.

Read more here.

Progress in 2020

When setting the price of our medicines in developed markets, we apply a value-based approach to balance reward for innovation with access and affordability. In developing countries we use innovative pricing structures to extend product reach. In least developed and low-income countries we do not file patents for our medicines and do not enforce historic patents.

Read more here.

Progress in 2020

We have reached over 267 million people since 2018 through access strategies, including tiered pricing and product donations. By the end of 2020, 80% of people living with HIV on antiretrovirals in low- and middle-income countries had access to a generic dolutegravir-containing product because of ViiV Healthcare's voluntary licensing agreements.

Read more here.

Progress in 2020​

In 2020, we exceeded this target and our access partnerships have reached 13.9 million people since 2018. This includes, in 2020, reaching over three million people through our partnership with Save the Children, Amref Health Africa and CARE International through our health worker training programme.

Read more here.

Progress in 2020

In 2020, a record 85% of people took time to feedback through our employee survey, and our engagement score increased 6% from 2019, to 84%.

Read more here.

Progress in 2020

In 2020, we set new aspirational targets for gender and for race and ethnicity, to improve representation at VP level and above, and introduced mandatory inclusion and diversity training for all employees. We signed up the Valuable 500 pledge, which involves developing a measurable and strategic three-year Disability confidence plan, and received recognition across a number of LGBT+ indices.

Read more here.

Our executive team has overseen our COVID-19 response, including the health, wellbeing and engagement of our employees as a primary focus. More than 22,000 employees completed online energy and resilience programmes, and we updated our One80 manager feedback tool to help managers understand where to focus their development.

Read more about health and wellbeing here, and development here.

Progress in 2020

We conducted 1,839 audits of our suppliers’ quality processes. Our pharmaceutical, vaccine and consumer manufacturing sites and local operating companies had 142 external regulatory inspections in 2020, with many carried out virtually due to the pandemic. Wherever necessary, we have robust processes in place to ensure corrective and preventive action plans are implemented in a timely manner.

Read more here.

Progress in 2020

We continue to report transparently on how we respond to employee policy violations, taking appropriate disciplinary action. We further improved visibility of labour rights risks in the supply chain in 2020. Working with external experts, we identified the raw materials and commodities that are sometimes linked to modern slavery and are now prioritising them for due diligence activities.

Read more here.

Progress in 2020

We evolved our privacy approach to better align with external expectations and the ‘privacy by design’ framework. We established a process to seek patient feedback on the design of our clinical trials, and continue to increase focus on improving diverse representation in clinical trials so that they represent the real world population in terms of age, race, ethnicity and gender.

Read more here.

Progress in 2020

We set ambitious new climate and nature goals and have been accredited for 1.5°C-aligned emissions reduction targets by the Science Based Targets initiative. We have joined RE100 and 52% of the electricity we used was sourced renewably. By the end of 2020, all of our sites had stopped sending waste to landfill.²

^{1 This commitment is supported by targets for carbon (including accreditation by the Science Based Targets Initiative), water, waste and deforestation-free sourcing.}

^{2 This achievement excludes waste, such as asbestos, that must be sent to landfill.}

Read more here.